| abstract |
The compounds described herein are related to the treatment of diabetes and / or hyperglycemia. More specifically, the compounds described are related to hypoglycemic insulin compounds that reduce blood glucose, pharmaceutical compositions containing these compounds, therapeutic use of these compounds, and intermediate compounds for the preparation of such halogenated insulin compounds. |